leisure time -WSS

leisure time

author：leisure time 2025-09-27 23:53:43 - browse：135

Without question, the new federal law banning surprise billing is achieving its goal of protecting patients from enormous medical bills. But in doing so, the measure, which was initially projected to lower federal spending, appears to be raising costs elsewhere.

The Biden administration’s new progress report on the process for arbitrating disagreements between insurance companies and providers, which covers the first six months of 2023, shows that in over 80% of payment disputes, the arbiter settled on an amount that was more than the median in-network rate for that service. In other words, insurers were ordered to pay more to an out-of-network provider than they’d pay to a contracted one. Not only that, the sheer volume of disputes means the three federal agencies that run the program are devoting much more time to it than expected.

“It raises concerns for folks that envisioned the arbitration process as helping to moderate costs rather than be a tool these companies can leverage to obtain even higher payments,” said Zachary Baron, the director of Georgetown University’s Health Policy and Law Initiative.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Micronoma's microbiome cancer diagnostic approach under fire

hotspot

WSS

Vertex non

New safety details link Apellis eye drug to rare cases of blindness

The woman behind the Dana Farber

CMS should re

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

hotspot

leisure time

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

Patients' immediate access to test results puts radiologists in a bind

Walensky prepares to leave CDC — and Congress — behind

EQRx, failed developer of low

Walensky prepares to leave CDC — and Congress — behind

Adults seen as increasingly susceptible to measles

Psychedelics group wrestles with new pharma identity

Chemotherapy shortages won’t get better under Biden’s latest plan

The high cost of giving birth even with insurance

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

entertainment

No plane should take off without an EpiPen onboard

Micronoma's microbiome cancer diagnostic approach under fire

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Patients' immediate access to test results puts radiologists in a bind

SCOTUS to consider access to abortion pill mifepristone

Spinal cord stimulation reduces pain in amputees, study finds

focus

hotspot

hotspot

focus